Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
Info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com
R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

September 22, 2026.

TO,
NSE LIMITED
EXCHANGE PLAZA, 5th FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
SYMBOL: INFINIUM

Dear Sir/Madam,

Sub: Intimation of Credit Rating

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that M/s. ICRA Limited has assigned new rating to the credit facilities of Infinium Pharmachem Limited as follows:

Instrument	**Current rated amount (Rs. Crore)**	**Rating action**
Long-term-Fund-based-Cash Credit	45.25	[ICRA]BBB (Stable); Assigned
Long-term-Fund-based-Term loan	6.84	[ICRA]BBB (Stable); Assigned
Long-term-Unallocated limits	0.11	[ICRA]BBB (Stable); Assigned

The copy of the rating letter issued by M/s. ICRA Limited is enclosed herewith and also available on their website www.icra.in .

The above information is also available on the website of the Company.

Kindly take the same on your records.

Thanking You,

For Infinium Pharmachem Limited

SANJAYKUMAR VITHTHALBHAI PATEL
Digitally signed by SANJAYKUMAR VITHTHALBHAI PATEL
Date: 2026.09.22 11:34:53 +05'30'

Sanjay Patel
Managing Director
DIN: 00370715

ICRA
Insights that empower

ICRA/INFINIUM PHARMACHEM LIMITED/21092026/1

Date: September 21, 2026

Mr. Nilesh Patel
Executive Director (Finance)
INFINIUM PHARMACHEM LIMITED
37-38 GIDC Sojitra Taluka: Sojitra
Dist: Anand, Sojitra,
Gujarat, 387240

Dear Sir,

Re: ICRA's Credit Rating for below mentioned Instruments of INFINIUM PHARMACHEM LIMITED

As per the Rating Agreement/Statement of Work executed with ICRA Limited, ICRA's Rating Committee has taken the following rating actions for the mentioned instruments of your company.

Instrument	Rated Amount (Rs. crore)	Rating Action[1]	Financial Sector Regulator[#]
Long-term - Fund-based - Cash credit	45.25	[ICRA]BBB(Stable); Assigned	RBI
Long-term - Fund-based - Term loan	6.84	[ICRA]BBB(Stable); Assigned	RBI
Long term – Unallocated limits	0.11	[ICRA]BBB(Stable); Assigned	RBI
Total	**52.20**		

[#]SEBI's grievance redressal/dispute resolution and SEBI investor protection mechanisms such as SCORES and ODR shall not be available for activities and instruments which fall under the regulatory purview of Financial Sector Regulators other than SEBI.

The aforesaid rating(s) will become due for surveillance within one year from the date of rating communication letter. However, ICRA reserves the right to review and/or, revise the above rating(s) at any time based on new information becoming available, or the required information not being available, or other circumstances that ICRA believes could have an impact on the rating(s). Therefore, request the lenders and investors to visit ICRA website at www.icra.in for latest rating(s) of the company.

The rating(s) are specific to the terms and conditions of the instruments as indicated to us by you, and any change in the terms or size of the same would require a review of the rating(s) by us. In case there is any change in the terms and conditions or the size of the rated instrument, the same must be brought to our notice before the instrument is used by you. In the event such changes occur after the rating(s) have been assigned by us and their use has been confirmed by you, the rating(s) would be subject to our review, following which there could be a change in the rating(s) previously assigned. Notwithstanding the foregoing, any change in the over-all limit of the instrument from that specified in this letter, would constitute an enhancement that would not be covered by or under the said Rating Agreement.

The rating(s) assigned must be understood solely as an opinion and should not be treated, or cause to be treated, as recommendation to buy, sell, or hold the rated instrument availed/issued by your company.

You are also requested to forthwith inform us about any default or delay in repayment of interest or principal amount of the instrument rated, as above, or any other debt instruments/ borrowing and keep us informed of any other developments which may have a direct or indirect impact on the debt servicing capability of the company including any

[1] Complete definitions of the ratings assigned are available at www.icra.in.

proposal for re-schedulement or postponement of the repayment programmes of the dues/ debts of the company with any lender(s) / investor(s), or occurrence of any significant development that could impact the ability of the company to raise funds such as restriction imposed by any authority from raising funds through issuance of debt securities through electronic bidding system. Further, you are requested to inform us immediately as and when the borrowing limit for the instrument rated, as above, or as prescribed by the regulatory authority(ies) is exceeded.

We look forward to your communication and assure you of our best services.

With kind regards,
Yours sincerely,
For ICRA Limited

SUPRIO BANERJEE

Digitally signed by SUPRIO BANERJEE
Date: 2026.09.21 12:25:56 +05'30'

Suprio Banerjee
Vice President & Co Group Head
supriob@icraindia.com

Annexure

Details of Bank Limits Rated by ICRA (Rated on Long-Term Scale)	Instrument Name	Amount (Rs. Crore)	Rating	Rating Assigned On
ICICI Bank Limited	Cash Credit	19.00	[ICRA]BBB(Stable)	September 15, 2026
State Bank of India	Cash Credit	26.25		
ICICI Bank Limited	Term Loans	3.72		
State Bank of India	Term Loans	3.12		
Not Applicable	Unallocated Limits	0.11		
Total		**52.20**		